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Results: 1466 patients from 149 centers in 24 countries were random-
ized to geﬁtinib (n=733) or docetaxel (n=733); 323 patients were of 
Asian racial origin. In the geﬁtinib and docetaxel treatment arms, 
respectively, 54% and 55% had adenocarcinoma, 36% and 33% were 
female, and 20% and 21% were never-smokers. 30%, 58%, 12% and 
25%, 63%, 12% had PS 0, 1, 2 in the geﬁtinib and docetaxel treatment 
arms, respectively and 15% and 17%, respectively, had undergone 2 
prior chemotherapy regimens. 453 patients provided a tumour sample 
giving at least one evaluable biomarker. Full results will be presented at 
the conference.
Conclusions: In this Phase III study comparing geﬁtinib with docetaxel 
in patients with locally advanced or metastatic NSCLC pretreated with 
platinum-based chemotherapy, the treatment groups were well balanced 
in terms of patient demographics and baseline characteristics. Full 
results will be presented at the conference.
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Background: Platinum-based chemotherapy is the standard of care for 
ﬁrst-line treatment of locally advanced and metastatic NSCLC. Gem-
citabine-cisplatin (GC) is a widely used doublet in this setting. In phase 
II studies, efﬁcacy results of pemetrexed-platinum doublets compare 
favorably with other active platinum-doublets. The combination of 
pemetrexed plus cisplatin (PC) has the potential to have similar efﬁcacy 
with more tolerability and more convenient administration. 
Methods: Patients with previously untreated stage IIIB or IV NSCLC 
and an ECOG PS of 0-1 were randomized to receive PC (P 500 mg/m2 
d1; C 75 mg/m2 d1) or GC (G 1250 mg/m2 d1,8; C 75 mg/m2 d1), every 
three weeks, up to 6 cycles. Both arms received folic acid, vitamin B12 
and dexamethasone. Randomization factors included stage, PS, gender, 
and history of brain metastases. The primary endpoint of this non-infe-
riority study was overall survival. Using the Cox proportional hazards 
model and a two-tailed 95% CI for the hazard ratio (HR), rejection of 
H0 occurs when the upper-bound of the HR CI is <1.17647, with an 
80% probability of rejecting H0 based on 1190 events. 
Results: From July 2004 to December 2005, 1725 patients were ran-
domized from 177 sites in 26 countries to PC (n=862) or GC (n=863). 
Both known prognostic factors and patient and disease characteristics 
were well-balanced between arms: median age 61 years, 70% male, 
64% PS 1, 76% stage IV NSCLC, 78% Caucasian, and 15% never 
smokers. Overall survival for patients randomized to PC was non-in-
ferior to GC (10.3 vs 10.3 mo [HR 0.94, 95%CI 0.84-1.05]), with the 
95% CI for HR included in the 1.176 non-inferiority margin. Progres-
sion free survival and response rates showed similarly robust non-
inferiority for PC vs GC (4.8 vs 5.1 mo [HR 1.04, 95%CI 0.94-1.15] 
and 31% vs 28%). Survival rates at 12 and 24 months were 43.5% 
vs 41.9% and 18.9% vs 14.0%, respectively. Hematologic grade 3/4 
drug-related toxicities were signiﬁcantly (p ≤ 0.001) lower for PC; 
neutropenia (15% vs 27%), anemia (6% vs 10%), and thrombocytope-
nia (4% vs 13%). Febrile neutropenia (grade 3/4, 1% vs 4%, p=0.002) 
and alopecia (12% vs 21%, p<0.001) were signiﬁcantly less for PC. 
Less grade 3/4 nausea (7% vs 4%, p=0.004) and anorexia (2% vs 1%, 
p=0.009) were observed for GC. In a pre-speciﬁed analysis of survival 
by histologic groups, PC had signiﬁcantly better survival than GC in 
adenocarcinoma (n=847, 12.6 vs 10.9 mo [HR 0.84, CI 0.71-0.98]) and 
in large cell histology (n=153, 10.4 vs 6.7 mo [HR 0.68, CI 0.48-0.97]). 
In contrast, there was a non signiﬁcant trend toward better survival with 
GC in squamous cell histology (n=473, 9.4 vs 10.8 mo [HR 1.22, CI 
0.99-1.50]). 
Conclusion: For ﬁrst-line treatment of advanced NSCLC, PC provides 
similar efﬁcacy with better tolerability and more convenient admin-
istration than GC. In addition, this is the ﬁrst NSCLC trial to report 
survival differences between platinum doublets according to histology, 
which may impact future treatment decisions.
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Background: Small cell lung cancer (SCLC) is a highly angiogenic tu-
mour. We hypothesized that thalidomide, an anti-angiogenic agent with 
tumour vasculature stabilizing, anti-cachexic and immuno-modulatory 
properties, when combined with chemotherapy and as maintenance 
treatment would improve survival in patients with poor prognosis 
SCLC. We previously demonstrated in a phase II study that low dose 
thalidomide when combined with chemotherapy and as maintenance 
agent was well tolerated without signiﬁcant toxicity (Lee, ASCO 
2002). Moreover, a randomized trial of 92 patients with extended-dis-
ease SCLC, who responded to chemotherapy, demonstrated a 3 month 
increase in survival in patients receiving thalidomide compared to 
placebo (Pujol ASCO 2006). Here, we present the preliminary results 
of a large randomised phase III trial of thalidomide in SCLC. 
Methods: Chemo-naive patients were entered into a double-blind 
placebo-controlled trial. Eligibility criteria included histologically or 
cytologically conﬁrmed SCLC, extensive or limited disease, age over 
18 years, ECOG performance status 0-3 and life expectancy of greater 
than 8 weeks. They were enrolled from 79 UK centres. All patients 
received up to 6 courses, every 3 weeks of Etoposide (120 mg/m2 IV on 
days 1 & 2, and 100mg bd given orally on day 3 or, given on day 2, in-
stead of IV, if required) and Carboplatin (AUC 5 or 6 given on day 1). 
Patients were randomized to receive placebo or thalidomide capsules, 
taken orally from starting chemotherapy, daily, for up to 2 years. The 
dose began at 100mg/day at the start of chemotherapy. If the patient 
was able to tolerate this dose, it was increased to 150mg/day at the end 
of chemotherapy for one month, then to 200mg/day for the rest of the 
trial. Thoracic radiotherapy and prophylactic cranial irradiation were 
offered to patients with initially limited disease who had a complete 
or partial response. Strict guidelines were given regarding contrace-
